Related Experiment Video
Updated: Apr 30, 2026
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
7.4K
Future of pharmacogenetics-based therapy for tuberculosis.
Tomoshige Matsumoto1, Masako Ohno, Junichi Azuma
1Department of Clinical Laboratory, Osaka Anti-Tuberculosis Association Osaka Hospital, Neyagawa, Osaka, Japan.
Pharmacogenomics
|May 7, 2014
Summary
Personalized tuberculosis (TB) therapy using NAT2 genotyping is safer and more effective than standard treatments. This pharmacogenetics-based approach offers improved outcomes for both active and latent TB infection (LTBI).
Area of Science:
- Pharmacogenetics
- Personalized Medicine
- Infectious Disease Research
Background:
- Current tuberculosis (TB) therapy lacks personalization, leading to variable patient outcomes.
- Genetic variations, specifically in the NAT2 polymorphism, significantly impact isoniazid's efficacy and toxicity across different populations.
- There is a need for tailored therapeutic strategies in TB management.
Purpose of the Study:
- To evaluate the safety and efficacy of a pharmacogenetics-based TB therapy.
- To propose novel therapeutic approaches for latent TB infection (LTBI) utilizing NAT2 genotyping.
- To highlight the potential of personalized medicine in TB treatment.
Main Methods:
- Implementation of a pharmacogenetics-based TB therapy regimen.
- NAT2 genotyping to guide treatment decisions.
- Comparison of outcomes between pharmacogenetics-based and standard TB therapies.
- Development of a schematic for LTBI therapeutic strategies using NAT2 genotyping.
Main Results:
- The pharmacogenetics-based TB therapy demonstrated superior safety and efficacy compared to standard therapy.
- NAT2 genotyping allows for personalized treatment adjustments, improving patient response.
- The proposed LTBI therapy using NAT2 genotyping is anticipated to be more effective and safer than current standard LTBI treatment.
Conclusions:
- Pharmacogenetics-based TB therapy represents a significant advancement over standard treatment protocols.
- NAT2 genotyping is a valuable tool for personalizing TB therapy, enhancing both safety and efficacy.
- This approach is a crucial step towards implementing personalized medicine in the management of TB and LTBI.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:28Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194